Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil

Cancer Research

Volumn 61, Issue 14, 2001, Pages 5447-5452

  Nakamura, H ^a   Mullen, J T ^a   Chandrasekhar, S ^a   Pawlik, T M ^a   Yoon, S S ^a   Tanabe, K K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; PRODRUG; RIBONUCLEOTIDE REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL DESTRUCTION; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVATION; DRUG METABOLISM; DRUG TRANSFORMATION; GENE DISRUPTION; GENE TARGETING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRION; VIRUS INFECTION; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MUTATION; NEOPLASMS, EXPERIMENTAL; NUCLEOSIDE DEAMINASES; PRODRUGS; SACCHAROMYCES CEREVISIAE; SURVIVAL ANALYSIS; VERO CELLS; VIRUS REPLICATION;

EID: 0035878715     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Human gene marker/therapy clinical protocols
2. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
3. Experimental therapy of human glioma by means of a genetically engineered virus mutant
4. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
5. Reovirus therapy of tumors with activated ras pathway
6. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpes virus
7. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
8. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
9. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
10. Cancer gene therapy using replication-competent herpes simplex virus type 1
11. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
12. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts
13. Mode of action of 5-fluorocytosine and mechanisms of resistance
14. S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells
15. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines
16. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
17. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
18. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
19. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system
20. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
21. 5-Fluoropyrimidines
22. Systemic therapy approaches for colorectal cancer
23. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
24. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
25. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified